TABLE 2.

Interpretive agreement between results of voriconazole disk diffusion tests and of standard 48-h BMDa

Organism (no. tested)Test methodc% of results in each categoryb% Agreementd% Errors
SSDDRVMEMEM
C. albicans (1,630)Ref.-MIC100.00.00.0
Ref.-disk99.80.10.199.80.00.10.1
Part.-disk98.20.11.798.20.01.70.1
C. glabrata (402)Ref.-MIC96.31.52.2
Ref.-disk96.00.33.797.30.50.51.7
Part.-disk84.17.28.784.80.56.08.7
C. parapsilosis (399)Ref.-MIC99.50.250.25
Ref.-disk99.00.80.299.00.00.01.0
Part.-disk91.73.84.592.00.04.04.0
C. tropicalis (325)Ref.-MIC99.70.00.3
Ref.-disk98.20.90.997.90.30.90.9
Part.-disk85.85.98.385.50.38.35.9
C. krusei (85)Ref.-MIC100.00.00.0
Ref.-disk98.81.20.098.80.00.01.2
Part.-disk89.45.94.789.40.04.75.9
All Candida species (2,934)Ref.-MIC99.40.20.4
Ref.-disk98.90.40.799.00.10.20.7
Part.-disk94.02.13.994.10.13.42.4
  • a Voriconazole disk diffusion testing was performed according to CLSI method M44-A, and voriconazole BMD MIC testing was performed according to CLSI method M27-A2.

  • b Voriconazole susceptibility categories are as follows: S, susceptible (MIC of ≤1 μg/ml, zone diameter of ≥17 mm); SDD, susceptible dose dependent (MIC of 2 μg/ml, zone diameter of 14 to 16 mm); R, resistant (MIC of ≥4 μg/ml, zone diameter of ≤13 mm).

  • c Ref.-MIC, MIC testing performed by ARTEMIS reference laboratory; Ref.-disk, disk testing performed by ARTEMIS reference laboratory; Part.-disk, disk testing performed by ARTEMIS participants.

  • d Percent categorical agreement between disk diffusion and MIC test results.